STYLE SHEET
GLOBAL CSS
COLORS
ANIMATIONS
MEDIA QUERY
SPACING SYSTEM

Anna Sommerfeld

M.Sc. in Molecular Biology, Senior Expert in Pharma & Medtech

Anna Sommerfeld is a molecular biologist by training and has more than 25 years of experience in the pharmaceutical industry, including roles at AstraZeneca, Roche and Gilead Sciences. As the founder of Mealsizer®, she has spent the past 15 years working closely with both obesity and eating disorder care, translating research into practical solutions for better health.

LinkedIn logo
Portrait imageOrange stylized human head with colorful flowers and vines growing out from the top and back.

Anna Sommerfeld holds a Master’s degree in Molecular Biology and has more than 25 years of experience in the pharmaceutical and medtech industries, including senior roles at leading companies such as AstraZeneca, Roche and Gilead Sciences. She has extensive experience working across therapeutic areas including infectious diseases, cardiometabolic conditions, CNS and nutrition, collaborating with both medical and commercial teams to translate scientific evidence into practice and making complex science accessible through clear communication. Anna is also the founder of Mealsizer®, an evidence-based portion control and nutrition tool, and for the past 15 years she has worked closely with obesity and eating disorder care, promoting healthy eating habits and nutritional interventions

Articles by

Anna Sommerfeld

Science and publications

Yazen at European Congress on Obesity (ECO) 2025: Pioneering Modern Obesity Treatment through Digital Innovation

At ECO 2025 in Malaga, Yazen unveiled digital solutions and personalised strategies that are revolutionising obesity management and enhancing outcomes.

Medicine

Fertility & Pregnancy: A Guide for Overweight Women

At Yazen, we focus on helping women lose weight — a key factor in improving fertility and increasing the chances of pregnancy — through expert, personalised care.

Medicine

Understanding Lipedema: symptoms, causes, and management

Lipedema is a misunderstood and often misdiagnosed condition that causes painful fat accumulation — Yazen explains the symptoms, causes, and treatment options.

Medicine

Understanding Polycystic Ovary Syndrome (PCOS)

Polycystic ovary syndrome (PCOS) affects millions of women—and at Yazen, we help you manage symptoms, improve fertility, and take control of your weight and health.

Medicine

Menopause and weight gain: Understanding the challenges and solutions with Yazen's support

Menopause often brings unexpected weight gain, but with Yazen’s expert support, women can take control of their health and feel confident through every stage.

Medicine

Understanding Hypothyroidism: A Common Condition Among Women

Hypothyroidism is a common condition, especially among British women—and at Yazen, we’re here to help you understand and manage it with confidence.

Medicine

Women and Weight: An Intersection of Physical and Mental Health

At Yazen, we support women through the physical, emotional, and hormonal aspects of weight—offering tailored treatment and compassionate care.

Science and publications

Sustainable Weight Loss and Health Benefits in Obesity Care: 18-Month Real-World-Evaluation Results in a Virtual Care Setting from Yazens First Operational Quality follow-up

This 18-month real-world evaluation data analysis demonstrates that Yazen Health’s fully digital care model, integrating pharmacological treatment and lifestyle intervention can provide effective, sustainable results in a real-world setting.
‍
Patients achieved a weight reduction of 16.6%, accompanied by improvements in metabolic health markers including laboratory values, despite medication supply limitations and without using the maximum recommended dose of semaglutide. 70% remained in the program after 12 months. Weight loss outcomes were comparable to those observed in RCTs such as the STEP trials1-2.
Science and publications

High Adherence to GLP-1 Receptor Agonists: 18-Month Outcomes from the Yazen Model

High adherence rates to GLP-1 receptor agonists within a structured, digitally based weight management programme, may contribute to improved long-term medication adherence.
‍

This real-world analysis from Yazens first large scale operational quality follow-up, demonstrates almost 70% compliance with GLP-1 medications at 12 months, surpassing earlier studies that showed 20-50%1-4. After 2 years*, 60% of patients were still in treatment.